Cell Reprogramming Patent, Asgard Therapeutics, 14th Apr

← USPTO Patent Grants

Composition for reprogramming cells into plasmacytoid dendritic cells or interferon type I-producing cells, methods and uses thereof

Grant US12600947B2 Kind: B2 Apr 14, 2026

Assignee

ASGARD THERAPEUTICS AB

Inventors

Carlos Filipe Ribeiro Lemos Pereira, Cristiana Ferreira Pires, Fábio Fiúza Rosa, Abigail Altman

Abstract

The present disclosure relates to compositions, constructs and vectors for reprogramming cells into plasmacytoid dendritic cells or interferon type I-producing cells, methods and uses thereof. The present disclosure relates to the development of methods for making plasmacytoid dendritic cells or interferon type I-producing cells that promote antiviral and anti-tumoral immune responses from differentiated, multipotent or pluripotent stem cells by introducing and expressing isolated/synthetic transcription factors. More particularly, the disclosure provides methods for obtain plasmacytoid dendritic cells or interferon type I-producing cells by direct cellular reprogramming with the surprisingly use of combinations of specific transcription factors.

CPC Classifications

C12N 5/0639 C12N 2501/60 C12N 15/63 A61K 40/19

Filing Date

2020-10-09

Application No.

17766369

Claims

6

View original document →